NCT03070782 - Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease | Biotech Hunter

Enrollment

286

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

July 26, 2018

Study Completion Date

November 13, 2018

Conditions

Elevated Lipoprotein(a)Cardiovascular Disease

Interventions

DRUG

ISIS 681257

ISIS 681257 solution for SC injection.

DRUG

Placebo

Sterile normal saline (0.9% NaCl)

Trial Locations (32)

2730

Clinical Site, Herlev

8800

Clinical Site, Viborg

10016

Clinical Site, New York

10029

Clinical Site, New York

13326

Clinical Site, Cooperstown

13353

Clinical Site, Berlin

17602

Clinical Site, Lancaster

19104

Clinical Site, Philadelphia

21201

Clinical Site, Baltimore

22042

Clinical Site, Falls Church

32216

Clinical Site, Jacksonville

33434

Clinical Site, Boca Raton

44195

Clinical Site, Cleveland

50937

Clinical Site, Cologne

53215

Clinical Site, Milwaukee

66160

Clinical Site, Kansas City

77030

Clinical Site, Houston

80909

Clinical Site, Colorado Springs

86326

Clinical Site, Cottonwood

90048

Clinical Site, Los Angeles

92103

Clinical Site, La Jolla

92648

Clinical Site, Huntington Beach

94305

Clinical Site, Stanford

97239

Clinical Site, Portland

02114

Clinical Site, Boston

02906

Clinical Site, Providence

G7H7K9

Clinical Site, Chicoutimi

H1T 1C8

Clinical Site, Montreal

H3H 2L9

Clinical Site, Montreal

G1V4W2

Clinical Site, Québec

K1Y4W7

Clinical Site, Ottawa

1105AZ

Clinical Site, Amsterdam